Over the last thirty years, medicine has made great progress in the treatment of infectious diseases, cardiovascular illness, and other lethal medical conditions. However, says Dr. Michael Har-Noy, most metastatic cancer is approached today with similar treatments that were used two or three decades ago: a combination of surgery, chemotherapy, and radiation. Aside from the use of monoclonal antibodies as adjuvant therapy and occasional attempts at developing individualized cancer vaccines, cancer therapy has not changed much in recent years.

Immunovative Therapies Ltd., a small, relatively new biotech company in Israel, is using a truly unique approach to treat metastatic cancer. Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, is developing proprietary drugs that “wake-up” a patient’s immune system and help it attack and destroy metastatic cells. Dr. Michael Har-Noy’s unique biologic compounds may create a whole new field of cancer therapy.

Dr. Michael Har-Noy, a world-renowned immunologist and scientist, spent several years at Hadassah Medical Center in Israel studying bone marrow transplant patients and identifying the immunologic characteristics of successful transplant patients that did not develop graft versus host disease. At Immunovative Therapies, Dr. Michael Har-Noy has used this data to create complex cellular-based drugs that, when administered to a patient with cancer, provoke the patient’s own immune system to attack the administered drug and in the process, attack the tumor cell as well. This unique and proprietary process of stimulating a patient’s own immune cells to scavenge and attack the metastatic cancer cells has been termed the Mirror EffectTM.

At Immunovative Therapies, Dr. Michael Har-Noy has developed and is testing three prototype compounds; AlloStim™, CryoStim™, and AlloVax™. As opposed to the anti-tumor effect of a bone marrow transplant, these drugs stimulate a tumor-killing immune response that has no potential host toxicity, as it is the patient’s own immune system, and not a foreign one, that initiates the cancer-killing process.

Medical researchers have, to date, been unable to reliably stimulate a patient’s immune system to seek out and kill malignant cells. Dr. Michael Har-Noy of Immunovative Therapies seems to have developed a way to facilitate this process, and in doing so may soon forever change medicine’s approach to cancer treatment.